Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Gains from Investment Securities (2023 - 2025)

Compass Therapeutics' Gains from Investment Securities history spans 3 years, with the latest figure at $17.2 million for Q3 2025.

  • For Q3 2025, Gains from Investment Securities changed N/A year-over-year to $17.2 million; the TTM value through Sep 2025 reached $17.2 million, changed N/A, while the annual FY2025 figure was $1.0 million, 92.7% down from the prior year.
  • Gains from Investment Securities for Q3 2025 was $17.2 million at Compass Therapeutics, up from $96000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $17.2 million in Q3 2025 and bottomed at $96000.0 in Q4 2024.
  • The 3-year median for Gains from Investment Securities is $3.0 million (2023), against an average of $5.2 million.
  • The largest YoY upside for Gains from Investment Securities was 39.62% in 2024 against a maximum downside of 39.62% in 2024.
  • A 3-year view of Gains from Investment Securities shows it stood at $159000.0 in 2023, then crashed by 39.62% to $96000.0 in 2024, then surged by 17778.12% to $17.2 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Gains from Investment Securities are $17.2 million (Q3 2025), $96000.0 (Q4 2024), and $3.4 million (Q1 2024).